Search Videos and More
News
Dana-Farber Researchers Receive AACR 2024 Scientific Achievement Awards
Christopher D.M. Fletcher, MD, Timothy R. Rebbeck, PhD, David Pellman, MD, and Gordon J. Freeman, PhD, will be recognized by the American Association for Cancer Research (AACR) with 2024 Scientific Achievement Awards.
News
Dana-Farber CEO Laurie Glimcher Has Always Been a Trail-Blazer and a Risk-Taker
Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.
News
Antibody-Drug Conjugates: A Cancer Therapy Revolution
Dana-Farber researchers explore how a novel therapy may benefit patients
News
Immunotherapy for Cancer: What it Is, How it Works, and Where it’s Going
Immunotherapy refers to treatments that use the body’s immune system to combat diseases. Immuno-oncology focuses on efforts to use the immune system as a weapon against cancer. The immune system is a collection of organs, tissues, specialized cells, and substances that protect the body against infection and disease. While the immune system can often handle very small tumors on its own, either by destroying them or keeping them from growing, it can sometimes fail — either because a tumor grows too large, the cancer cells are too well camouflaged, or the tumor cells are able to stave off an immune system attack. A key discovery, made by Dana-Farber’s Gordon Freeman, PhD, and others, was that the immune system’s attack on cancer often falls short because many cancer cells display proteins, called immune checkpoint proteins, that bring the attack to a halt.
News
Melanoma Vaccine: Progress and Possibility
A melanoma therapeutic vaccine is a type of personalized cancer vaccine that is intended to train the immune system to fight cancer cells in a way that lasts many years. These novel vaccines are personally tailored to recognize the mutations present in an individual’s tumor cells. They are different from vaccines for infectious diseases, which are typically given to as many people as possible in a community to prevent a virus from spreading. Currently, no personalized melanoma vaccines are approved medicines, though several have been tested in clinical trials. A personalized RNA vaccine has recently shown promising data in patients with high-risk melanoma.
News
Immunotherapy Post-Surgery Improves Overall Survival For Kidney Cancer
For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence, according to an analysis of results from the KEYNOTE-564 study. Pembrolizumab was associated with a 38% reduction in risk of death compared with placebo.
News
Psilocybin Eases Depression in Patients with Cancer, Study Finds
For patients with cancer who are suffering from major depression, treatment with psilocybin plus individual and group psychological support can significantly relieve depressive symptoms, a clinical trial has found. In a companion study led by Dana-Farber Cancer Institute investigators, trial participants said the treatment experience with psilocybin – a hallucinogenic compound derived from certain mushrooms – created a sense of connection, meaning, and transcendence that aided the healing process.
News
Exploring How CAR T-Cell Therapy May Help More Patients
CAR T-cell therapy burst onto the scene as a revolutionary treatment for cancer patients in 2015, when it was introduced in clinical trials primarily for patients with lymphoma and leukemia. Since then, it has transformed the course of disease, primarily for blood cancer patients, with many clinical trials now exploring the approach for solid tumor patients. Through this highly tailored form of immune effector cell (IEC) therapy, typically a patient's own immune cells — known as T cells — are genetically re-engineered to identify and kill cancer cells.
News
Dana-Farber Research Publication 01.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Research Publication 12.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Research Publication 12.1.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Symposium
American Society of Hematology (ASH) 2023
Review presentations and information shared by Dana-Farber physician-scientists at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego.